Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Ann Hematol. 2021 Sep;100(9):2293-2302. doi: 10.1007/s00277-021-04473-4. Epub 2021 May 15.
Despite the clinical value of HMGB1 in non-Hodgkin lymphoma (NHL), the impact of HMGB1 protein expression on survival of patients with mature T-cell and NK-cell lymphoma (T/NK-CL) is unknown. Here, we evaluated correlations of HMGB1 expression in tumor tissues with pathophysiological characteristics of disease and determined the prognostic value of HMGB1 expression in relapsed/refractory T/NK-CL. HMGB1 expression was detected by immunohistochemistry (IHC) in 66 cases of relapsed/refractory T/NK-CL, and specimens were classified as high or low HMGB1 expression. Univariate and multivariate Cox regression analyses identified prognostic factors associated with progression-free survival (PFS) and overall survival (OS). High HMGB1 expression was significantly correlated with increased Ki67 levels and progressive lymphoma subtypes. Univariate Cox regression analysis showed that high HMGB1 expression was associated with unfavorable PFS (P = 0.006) and poorer OS (P < 0.001). Prognostic factors identified by univariate analysis were prognostic index for peripheral T-cell lymphoma non-specified (PIT) score ≥ 2, bone marrow involvement, Ki67 ≥ 70%, and high HMGB1 expression. Multivariate Cox regression analysis revealed that high HMGB1 expression was an independent prognostic factor for poorer PFS [hazard ratio (HR) 3.593; 95% confidence interval (CI) 1.171-11.027; P = 0.025] and OS [HR 7.663; 95% CI 2.367-24.803; P = 0.001]. A proposal prognostic model combining HMGB1 and Ki67 expression showed improved prognostic capacity and may help guide treatment planning. High HMGB1 expression may be a promising prognostic predictor and a potential therapeutic target for relapsed/refractory T/NK-CL. Furthermore, to apply HMGB1 as one of the best bio-maker, an external independent control cohort is needed.
尽管高迁移率族蛋白 B1（HMGB1）在非霍奇金淋巴瘤（NHL）中具有临床价值，但 HMGB1 蛋白表达对成熟 T 细胞和自然杀伤（NK）细胞淋巴瘤（T/NK-CL）患者生存的影响尚不清楚。在这里，我们评估了肿瘤组织中 HMGB1 表达与疾病病理生理特征的相关性，并确定了 HMGB1 表达在复发/难治性 T/NK-CL 中的预后价值。我们通过免疫组织化学（IHC）检测了 66 例复发/难治性 T/NK-CL 患者的 HMGB1 表达，并将标本分为高或低 HMGB1 表达。单因素和多因素 Cox 回归分析确定了与无进展生存期（PFS）和总生存期（OS）相关的预后因素。高 HMGB1 表达与 Ki67 水平升高和进展性淋巴瘤亚型显著相关。单因素 Cox 回归分析显示，高 HMGB1 表达与不良的 PFS（P = 0.006）和较差的 OS（P < 0.001）相关。单因素分析确定的预后因素包括外周 T 细胞淋巴瘤非特指（PIT）评分≥2、骨髓受累、Ki67≥70%和高 HMGB1 表达。多因素 Cox 回归分析显示，高 HMGB1 表达是较差 PFS 的独立预后因素[风险比（HR）3.593；95%置信区间（CI）1.171-11.027；P = 0.025]和 OS（HR 7.663；95%CI 2.367-24.803；P = 0.001）。结合 HMGB1 和 Ki67 表达的建议预后模型显示出改善的预后能力，可能有助于指导治疗计划。高 HMGB1 表达可能是一种有前途的预后预测因子和复发/难治性 T/NK-CL 的潜在治疗靶点。此外，为了将 HMGB1 用作最佳生物标志物之一，需要一个外部独立的对照队列。
